Cochrane · systematic review · CD006049
Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease
Diana, A, Pillai, R, Bongioanni, P, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 33.3%High 4 · 66.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: people with ALS/MND
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Survival at 1 year Estimated survival at 1 year based on trials of 6 and 9 months' duration | no estimate extracted | 2 studies · 355 participants | High |
Rate of decline in MVIC Expressed as arm megascore1 | no estimate extracted | 2 studies · 345 participants | High |
Rate of decline of % predicted FVC | no estimate extracted | 2 studies · 274 participants | High |
Rate of decline (per month) of functional rating scale (over a period of 9 months) Measured by ALSFRS‐R | no estimate extracted | 1 study · 128 participants | Moderate Downgraded: imprecision |
Health‐related quality of life Short Form 12 Health Survey (SF‐12) | no estimate extracted | 1 study · 128 participants | Moderate Downgraded: imprecision |
Adverse events | no estimate extracted | 2 studies · 353 participants | High |